Pint Pharma has announced that the General Directorate of Medicines Supplies and Drugs (DIGEMID) in Peru has announced the approval of ORLADEYO (berotralstat) for prophylaxis of hereditary angioedema (HAE) attacks in adults and children 12 years and older.

Hereditary angioedema is a genetic disorder that causes recurrent episodes of sudden, painful swelling of the skin, mucous membranes, and submucosal tissues. Until recently, treatment options for HAE were limited, which left patients facing a compromised quality of life and the constant risk of serious attacks.

“The approval of Orladeyo by DIGEMID is excellent news for the community of patients with hereditary angioedema in Peru,” commented Dr. Valnei Canutti, Scientific Director of Pint Pharma.

“This innovative oral therapy represents a breakthrough for those living with this rare condition, offering an effective and convenient long-term prophylaxis option, preventing hereditary angioedema attacks,” added Dr. Valnei Canutti.

According to David Muñoz, CEO of Pint Pharma, “Besides providing direct benefits to patients, the availability of Orladeyo in Peru highlights our continuous commitment to the advancement of research and innovation in the field of medical care for rare diseases.”

“The approval of Orladeyo is a great achievement for patients and proof of the successful collaboration among the medical community, regulators, and pharmaceutical companies in Peru to improve treatment options,” expressed Mauricio Botero, General Manager of Pint Pharma in the LATAM North Cluster.